The psoriasis-associated D10N variant of the adaptor Act1 with impaired regulation by the molecular chaperone hsp90 (original) (raw)

• Lowes, M.A., Bowcock, A.M. & Krueger, J.G. Pathogenesis and therapy of psoriasis. Nature 445, 866–873 (2007).
  Article CAS PubMed Google Scholar
• Nickoloff, B.J. & Nestle, F.O. Recent insights into the immunopathogenesis of psoriasis provide new therapeutic opportunities. J. Clin. Invest. 113, 1664–1675 (2004).
  Article CAS PubMed PubMed Central Google Scholar
• Chan, J.R. et al. IL-23 stimulates epidermal hyperplasia via TNF and IL-20R2-dependent mechanisms with implications for psoriasis pathogenesis. J. Exp. Med. 203, 2577–2587 (2006).
  Article CAS PubMed PubMed Central Google Scholar
• Bettelli, E. et al. Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature 441, 235–238 (2006).
  Article CAS PubMed Google Scholar
• Harrington, L.E. et al. Interleukin 17-producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages. Nat. Immunol. 6, 1123–1132 (2005).
  Article CAS PubMed Google Scholar
• Iwakura, Y. & Ishigame, H. The IL-23/IL-17 axis in inflammation. J. Clin. Invest. 116, 1218–1222 (2006).
  Article CAS PubMed PubMed Central Google Scholar
• Park, H. et al. A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17. Nat. Immunol. 6, 1133–1141 (2005).
  Article CAS PubMed PubMed Central Google Scholar
• Ouyang, W. Distinct roles of IL-22 in human psoriasis and inflammatory bowel disease. Cytokine Growth Factor Rev. 21, 435–441 (2010).
  Article CAS PubMed Google Scholar
• Res, P.C. et al. Overrepresentation of IL-17A and IL-22 producing CD8 T cells in lesional skin suggests their involvement in the pathogenesis of psoriasis. PLoS ONE 5, e14108 (2010).
  Article CAS PubMed PubMed Central Google Scholar
• Caruso, R. et al. Involvement of interleukin-21 in the epidermal hyperplasia of psoriasis. Nat. Med. 15, 1013–1015 (2009).
  Article CAS PubMed Google Scholar
• Cho, J.S. et al. IL-17 is essential for host defense against cutaneous Staphylococcus aureus infection in mice. J. Clin. Invest. 120, 1762–1773 (2010).
  Article PubMed PubMed Central Google Scholar
• Conti, H.R. et al. Th17 cells and IL-17 receptor signaling are essential for mucosal host defense against oral candidiasis. J. Exp. Med. 206, 299–311 (2009).
  Article CAS PubMed PubMed Central Google Scholar
• Chang, S.H., Park, H. & Dong, C. Act1 adaptor protein is an immediate and essential signaling component of interleukin-17 receptor. J. Biol. Chem. 281, 35603–35607 (2006).
  CAS PubMed Google Scholar
• Qian, Y. et al. The adaptor Act1 is required for interleukin 17-dependent signaling associated with autoimmune and inflammatory disease. Nat. Immunol. 8, 247–256 (2007).
  CAS PubMed Google Scholar
• Sonder, S.U. et al. IL-17-induced NF-κB activation via CIKS/Act1: physiologic significance and signaling mechanisms. J. Biol. Chem. 286, 12881–12890 (2011).
  Article CAS PubMed PubMed Central Google Scholar
• Schwandner, R., Yamaguchi, K. & Cao, Z. Requirement of tumor necrosis factor receptor-associated factor (TRAF)6 in interleukin 17 signal transduction. J. Exp. Med. 191, 1233–1240 (2000).
  Article CAS PubMed PubMed Central Google Scholar
• Liu, C. et al. Act1, a U-box E3 ubiquitin ligase for IL-17 signaling. Sci. Signal. 2, ra63 (2009).
  PubMed PubMed Central Google Scholar
• Kang, Z. et al. Astrocyte-restricted ablation of interleukin-17-induced Act1-mediated signaling ameliorates autoimmune encephalomyelitis. Immunity 32, 414–425 (2010).
  Article CAS PubMed PubMed Central Google Scholar
• Swaidani, S. et al. The critical role of epithelial-derived Act1 in IL-17- and IL-25-mediated pulmonary inflammation. J. Immunol. 182, 1631–1640 (2009).
  Article CAS PubMed Google Scholar
• Qian, Y. et al. Act1, a negative regulator in CD40- and BAFF-mediated B cell survival. Immunity 21, 575–587 (2004).
  Article CAS PubMed Google Scholar
• Matsushima, Y. et al. An atopic dermatitis-like skin disease with hyper-IgE-emia develops in mice carrying a spontaneous recessive point mutation in the Traf3ip2 (Act1/CIKS) gene. J. Immunol. 185, 2340–2349 (2010).
  Article CAS PubMed Google Scholar
• Strange, A. et al. A genome-wide association study identifies new psoriasis susceptibility loci and an interaction between HLA-C and ERAP1. Nat. Genet. 42, 985–990 (2010).
  Article CAS PubMed PubMed Central Google Scholar
• Ellinghaus, E. et al. Genome-wide association study identifies a psoriasis susceptibility locus at TRAF3IP2. Nat. Genet. 42, 991–995 (2010).
  Article CAS PubMed PubMed Central Google Scholar
• Huffmeier, U. et al. Common variants at TRAF3IP2 are associated with susceptibility to psoriatic arthritis and psoriasis. Nat. Genet. 42, 996–999 (2010).
  Article CAS PubMed PubMed Central Google Scholar
• Sun, D. et al. Treatment with IL-17 prolongs the half-life of chemokine CXCL1 mRNA via the adaptor TRAF5 and the splicing-regulatory factor SF2 (ASF). Nat. Immunol. 12, 853–860 (2011).
  CAS PubMed PubMed Central Google Scholar
• Zhu, S. et al. Modulation of experimental autoimmune encephalomyelitis through TRAF3-mediated suppression of interleukin 17 receptor signaling. J. Exp. Med. 207, 2647–2662 (2010).
  Article CAS PubMed PubMed Central Google Scholar
• Taipale, M., Jarosz, D.F. & Lindquist, S. HSP90 at the hub of protein homeostasis: emerging mechanistic insights. Nat. Rev. Mol. Cell Biol. 11, 515–528 (2010).
  Article CAS PubMed Google Scholar
• Trepel, J., Mollapour, M., Giaccone, G. & Neckers, L. Targeting the dynamic HSP90 complex in cancer. Nat. Rev. Cancer 10, 537–549 (2010).
  Article CAS PubMed PubMed Central Google Scholar
• Cerchietti, L.C. et al. A purine scaffold Hsp90 inhibitor destabilizes BCL-6 and has specific antitumor activity in BCL-6-dependent B cell lymphomas. Nat. Med. 15, 1369–1376 (2009).
  Article CAS PubMed PubMed Central Google Scholar
• Marubayashi, S. et al. HSP90 is a therapeutic target in JAK2-dependent myeloproliferative neoplasms in mice and humans. J. Clin. Invest. 120, 3578–3593 (2010).
  Article CAS PubMed PubMed Central Google Scholar
• Orthwein, A. et al. Regulation of activation-induced deaminase stability and antibody gene diversification by Hsp90. J. Exp. Med. 207, 2751–2765 (2010).
  Article CAS PubMed PubMed Central Google Scholar
• Weigert, O. et al. Genetic resistance to JAK2 enzymatic inhibitors is overcome by HSP90 inhibition. J. Exp. Med. 209, 259–273 (2012).
  Article CAS PubMed PubMed Central Google Scholar
• Schulz, R. et al. Inhibiting the HSP90 chaperone destabilizes macrophage migration inhibitory factor and thereby inhibits breast tumor progression. J. Exp. Med. 209, 275–289 (2012).
  Article CAS PubMed PubMed Central Google Scholar
• Waza, M. et al. 17-AAG, an Hsp90 inhibitor, ameliorates polyglutamine-mediated motor neuron degeneration. Nat. Med. 11, 1088–1095 (2005).
  Article CAS PubMed Google Scholar
• Bulek, K. et al. The inducible kinase IKKi is required for IL-17-dependent signaling associated with neutrophilia and pulmonary inflammation. Nat. Immunol. 12, 844–852 (2011).
  Article CAS PubMed PubMed Central Google Scholar
• Ho, A.W. et al. IL-17RC is required for immune signaling via an extended SEF/IL-17R signaling domain in the cytoplasmic tail. J. Immunol. 185, 1063–1070 (2010).
  Article CAS PubMed Google Scholar
• Ryzhakov, G., Blazek, K. & Udalova, I.A. Evolution of vertebrate immunity: sequence and functional analysis of the SEFIR domain family member Act1. J. Mol. Evol. 72, 521–530 (2011).
  Article CAS PubMed Google Scholar
• Liang, S.C. et al. IL-22 induces an acute-phase response. J. Immunol. 185, 5531–5538 (2010).
  Article CAS PubMed Google Scholar
• Guilloteau, K. et al. Skin inflammation induced by the synergistic action of IL-17A, IL-22, oncostatin M, IL-1α, and TNF-α recapitulates some features of psoriasis. J. Immunol. (2010).
• Hu, Y. et al. IL-17RC is required for IL-17A- and IL-17F-dependent signaling and the pathogenesis of experimental autoimmune encephalomyelitis. J. Immunol. 184, 4307–4316 (2010).
  Article CAS PubMed Google Scholar
• Annunziato, F., Cosmi, L., Liotta, F., Maggi, E. & Romagnani, S. Type 17 T helper cells-origins, features and possible roles in rheumatic disease. Nat. Rev. Rheumatol. 5, 325–331 (2009).
  Article CAS PubMed Google Scholar
• Zheng, Y. et al. Interleukin-22, a TH17 cytokine, mediates IL-23-induced dermal inflammation and acanthosis. Nature 445, 648–651 (2007).
  Article CAS PubMed Google Scholar
• Ma, H.L. et al. IL-22 is required for Th17 cell-mediated pathology in a mouse model of psoriasis-like skin inflammation. J. Clin. Invest. 118, 597–607 (2008).
  CAS PubMed PubMed Central Google Scholar
• Van Belle, A.B. et al. IL-22 is required for imiquimod-induced psoriasiform skin inflammation in mice. J. Immunol. 188, 462–469 (2012).
  Article CAS PubMed Google Scholar
• Rizzo, H.L. et al. IL-23-mediated psoriasis-like epidermal hyperplasia is dependent on IL-17A. J. Immunol. 186, 1495–1502 (2011).
  Article CAS PubMed Google Scholar
• Li, L.F., Sujan, S.A., Yang, H. & Wang, W.H. Serum immunoglobulins in psoriatic erythroderma. Clin. Exp. Dermatol. 30, 125–127 (2005).
  Article PubMed Google Scholar
• Saraceno, R., Scotto, G., Chiricozzi, A. & Chimenti, S. Urticaria associated with hyper-IgE in a patient with psoriasis undergoing treatment with efalizumab. Acta Derm. Venereol. 89, 412–413 (2009).
  Article PubMed Google Scholar
• Li, X.L. et al. Unusual psoriasiform lesions in a patient with Hyper-IgE syndrome. J. Eur. Acad. Dermatol. Venereol. 21, 424–426 (2007).
  Article CAS PubMed Google Scholar
• Awasthi, A. et al. Cutting edge: IL-23 receptor GFP reporter mice reveal distinct populations of IL-17-producing cells. J. Immunol. 182, 5904–5908 (2009).
  Article CAS PubMed Google Scholar
• Swaidani, S. et al. T cell-derived Act1 is necessary for IL-25-mediated Th2 responses and allergic airway inflammation. J. Immunol. 187, 3155–3164 (2011).
  Article CAS PubMed Google Scholar